What adjuvant clinical trial is more promising for papillary rcc and why
According to the most recent NCCN Guidelines for Kidney Cancer (2024), there are currently several important adjuvant trials, but the most promising data comes from the KEYNOTE-564 trial using pembrolizumab, which has shown significant benefits in disease-free survival (DFS). However, it's important to note that this trial included mainly clear cell RCC patients, with limited papillary RCC representation.
For papillary RCC specifically, according to the European Society for Medical Oncology (ESMO) guidelines, two trials are particularly noteworthy:
- The MK-3475-B16/KEYNOTE-B16 trial
- Specifically designed for non-clear cell RCC including papillary
- Investigating pembrolizumab in the adjuvant setting
- Currently ongoing and actively recruiting
- The PROSPER trial (EA8143)
- Investigating perioperative nivolumab
- Includes papillary RCC patients
- Has potential to be particularly promising due to its novel perioperative approach
The National Cancer Institute (NCI) clinical trials database indicates that the KEYNOTE-B16 trial may be the most promising specifically for papillary RCC because:
- It's the first adjuvant trial specifically designed to include a substantial proportion of non-clear cell RCC patients
- It builds on the successful safety profile established in KEYNOTE-564
- It addresses an unmet need in papillary RCC treatment
However, I must emphasize that you should discuss clinical trial participation with your oncology team, as eligibility criteria and availability vary. Your healthcare providers can best determine which trial might be most appropriate for your specific situation.
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Grounded in NCCN Guidelines for Patients: Kidney Cancer — the same guidelines oncologists use.
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated October 15, 2025. Informational only — not a substitute for your oncology team.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Source Guidelines
NCCN Guidelines for Patients: Kidney Cancer (2026)Browse all NCCN Guidelines for Patients →Related Services
Services that may help with clinical trials for Kidney Cancer patients
Have your records handy? Add them to a private case for a deeper, personalized read →
More questions about Kidney Cancer
- What clinical trials are available for locally advanced Kidney Cancer
- What are the odds of a clinical trial being successful in my case
- What is the difference between adjuvant and neoadjuvant treatment for Kidney Cancer
- Describe the EVEREST trial to me
- What follow-up tests do I need after Kidney Cancer treatment ends
- My Kidney Cancer came back — what are my options now
- How will I know if my Kidney Cancer treatment is working
- How do I prepare for Kidney Cancer surgery